A Study of AMG 337 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

December 8, 2010

Primary Completion Date

October 1, 2015

Study Completion Date

December 13, 2016

Conditions
Advanced MalignancyAdvanced Solid TumorsCancerOncologyOncology PatientsTumors
Interventions
DRUG

AMG 337

AMG 337 is a small molecule inhibitor of c-Met which is a receptor tyrosine kinase expressed on the surface of epithelial cells.

Trial Locations (8)

30332

Research Site, Atlanta

37232

Research Site, Nashville

43210

Research Site, Columbus

48201

Research Site, Detroit

60637

Research Site, Chicago

77030

Research Site, Houston

90025

Research Site, Los Angeles

02114

Research Site, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY